A5024725726- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Angiogenesis and VEGF in Cancer
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Cardiac Imaging and Diagnostics
- Peptidase Inhibition and Analysis
- Coronary Interventions and Diagnostics
- Immune cells in cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Medical Imaging Techniques and Applications
- Chemotherapy-related skin toxicity
- Cancer Immunotherapy and Biomarkers
- Congenital Heart Disease Studies
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
Kumamoto University Hospital
2013-2025
Kumamoto University
2015-2024
Kawasaki Medical School
2023-2024
Shizuoka General Hospital
2024
Kyoto University Hospital
2023
St. Marianna University School of Medicine
1980-2022
University of Tokyo Hospital
2022
Aichi Cancer Center
2016-2022
Nagoya City University
2022
Mie University Hospital
2022
Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) investigational HER3-targeted antibody-drug conjugate that being evaluated as a novel treatment HER3-expressing advanced cancer the U31402-A-J101 study.Adults disease progression on previous therapies were eligible. Patients dose-escalation, dose-finding, and dose-expansion parts received HER3-DXd 1.6-8.0 mg/kg...
Recent clinical studies have demonstrated that tumor angiogenesis is a potent prognostic indicator for breast cancer patients. The quantitation of endothelial growth factors thought to be useful assess angiogenic phenotype in the tumor. Among many new factors, vascular factor (VEGF) known particularly responsible promoting neovascularization human cancer.Intratumoral protein levels VEGF were measured by enzymatic immunoassay 135 primary tissues. compared with microvessel density evaluated...
Strategies to inhibit metastasis have been mainly unsuccessful in part due insufficient mechanistic understanding. Here, we report evidence of critical role for the angiopoietin-like protein 2 (ANGPTL2) metastatic progression. In mice, Angptl2 has implicated inflammatory carcinogenesis but it not studied human tumors. patients with lung cancer, elevated levels ANGPTL2 expression tumor cells within primary were associated a reduction period disease-free survival after surgical resection....
// Aiko Sueta 1 , Yutaka Yamamoto Mai Tomiguchi Takashi Takeshita Mutsuko Yamamoto-Ibusuki 2 and Hirotaka Iwase Department of Breast Endocrine Surgery, Kumamoto University Graduate School Medical Sciences, 860-8556, Japan Molecular-Targeting Therapy for Cancer, Hospital, Correspondence to: Yamamoto, email: ys-yama@triton.ocn.ne.jp Keywords: exosome, microRNA, breast cancer, circulating biomarker, prognostic factor Received: April 19, 2017     Accepted: June 28, Published:...
Recent studies have indicated the clinical significance of tumor‐associated macrophages ( TAM ) in several malignant tumors including breast cancer. Although recent focused on CD 68‐positive or 163‐positive cancer, no study has investigated 204‐positive We found that 204 expression was evaluated following stimulation with conditioned medium CM cancer cell lines. Paraffin sections 149 samples which were diagnosed as invasive ductal carcinoma immunohistochemically analyzed for 68, 163 and...
The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether results can clinical response neoadjuvant letrozole.NEOS phase 3 trial hormonal therapy ± chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months letrozole and surgery. TransNEOS had tumors ≥ 2 cm archived core-biopsy samples taken before...
Adjuvant trastuzumab monotherapy has not been compared with + chemotherapy. We investigated the relative value of for older patients breast cancer.This study was an open-label, randomized controlled a treatment selection design in which noninferiority criterion predefined. Patients aged 70-80 years surgically treated human epidermal growth factor receptor 2-positive invasive cancer received or The primary end point disease-free survival (DFS) assessment prespecified hazard ratio (HR),...
1002 Background: Patritumab deruxtecan (HER3-DXd) is a novel, investigational ADC composed of human anti-HER3 monoclonal antibody covalently bound to topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. Here we report updated safety and efficacy data from this ongoing study (U31402-A-J101; NCT02980341; JapicCTI-163401) HER3-DXd in pts with previously treated MBC. Methods: U31402-A-J101 phase 1/2, multicenter, open-label, first-in-human HER3-expressing MBC (N =...
The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. guidelines consist 12 background questions (BQs), 33 clinical (CQs), and 20 future research (FRQs). Multiple outcomes including efficacy safety selected each CQ, then quantitative qualitative systematic reviews conducted determine strength evidence recommendation, which was finally determined voting among designated...
In the primary analysis of open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared (TC) in patients human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall (OS) at median follow-up 25.8 months. Patients who have previously received pertuzumab-containing...
Abstract We have investigated the expression of platelet‐derived endothelial‐cell growth factor/thymidine phosphorylase (PD‐ECGF/dThdPase) in human breast‐cancer tissues by immunocytochemical method using anti‐PD‐ECGF/dThdPase monoclonal antibody. Out 100 invasive‐ductal‐carcinoma tissue samples, 39 (39%) were evaluated as PD‐ECGF/dThdPase‐positive. The PD‐ECGF/dThdPase was identified mainly cytoplasma tumor cells. significantly associated with microvessel density assessed immunostaining to...
Keywords: nab-paclitaxel, breast cancer, toxicity profile
The immune status of patients can impact on the clinical course cancer. Lymph node (LN) macrophages play critical roles in anti-cancer immunity via activation cytotoxic T-lymphocytes (CTLs). In this study, prognostic significance CD169+ LN was examined with breast For purpose number cells and their ratio relative to total (CD68+) regional LNs (RLNs), as well CD8+ CTLs tumor tissues, were investigated using immunohistochemistry paraffin-embedded tissue samples from 146 association these data...
Abstract The Japanese Breast Cancer Society Clinical Practice Guidelines are published as timely guidance on clinical issues in breast cancer treatment Japan. In the recent edition of these guidelines, we addressed a new question 34 (CQ 34, systemic part) “Is trastuzumab deruxtecan recommended for patients with unresectable or metastatic HER2-low cancer?” and future research 7 (FRQ 7, pathological diagnosis “How is diagnosed indication deruxtecan?”. These questions address use who have...
Estrogen receptor (ER) α plays a crucial role in normal breast development and has also been linked to mammary carcinogenesis clinical outcome cancer patients. However, the molecular mechanisms controlling expression of ERα are as yet not fully understood. Gene amplification is one important factors regulating protein expression. Recent studies on ESR1 gene, which encodes ERα, have presented conflicting data. Using fluorescence situ hybridization real‐time quantitative polymerase chain...
FBXW7 is a cell cycle regulatory gene that ubiquitinates positive regulators such as c‐Myc and cyclin E, allowing for exit. Defects in the lead to re‐entry expedite G1‐S transition thought be one of causes cancer development. However, its clinical importance breast patients remains undetermined. This prompted us investigate expression level establish significance. The mRNA was assessed 186 cases primary invasive cancer. Correlations between clinicopathological factors, prognoses...